The KRAS inhibitor sotorasib is newly approved for one kind of lung cancer; Vanderbilt researchers ask if it should be considered for another type if the tumor has the gene mutation it targets.

Vanderbilt's Eden Biltibo, MD, a clinical fellow in the Division of Hematology and Oncology, has been selected for the 2022 ASH-CIBMTR-ASTCT Career Development Award.

Jordan Berlin, MD, has been appointed interim leader of Vanderbilt's Division of Hematology and Oncology in the Department of Medicine.

Vanderbilt's Brent Ferrell, MD, is one of the recipients a 2022 Endeavor Award from the The Mark Foundation for Cancer Research.

A study by Vanderbilt and New York City researchers found that 9/11 first responders to the World Trade Center have increased levels of mutations that escalate their risk for blood cancers or cardiovascular disease

Ben Ho Park, MD, PhD, deputy director of the Vanderbilt-Ingram Cancer Center, has been named the center’s new director.

Kure It Cancer Research has awarded a $200,000 grant to support kidney cancer research by Vanderbilt's Scott Haake, MD.